On September 26th, Anzhen Hospital witnessed an important milestone in the medical technology field - the launch meeting of the Class III HA medical device clinical trial. This meeting marks the official collaboration between Xienfei (Beijing) Technology and Trade Co., Ltd., Beijing Huanmu Medical Technology Co., Ltd., and Beijing Anzhen Hospital Affiliated to Capital Medical University, entering a new chapter of deep cooperation.

The Department of Plastic Surgery, Aesthetics and Laser Medicine at Beijing Anzhen Hospital Affiliated to Capital Medical University was established in 1983 and has a thirty-year history. Initially established as a laser department, it was one of the earliest professional departments in China to apply advanced laser technology in clinical surgical treatment. The department has not only steadily developed in the domestic market but also actively engages in international medical aesthetic exchanges and cooperation, continuously improving its professional level and international influence. This clinical trial launch meeting has gathered industry elites and cutting-edge technology, with an expected participation of nearly 200 subjects. This not only serves as a comprehensive test of product performance but also as a strong endorsement of the scientific nature and safety of Xienfei's upcoming new products.

REJUVIEL, originating from Korea's PharmaResearch company, is a series of injectable cross-linked sodium hyaluronate products, including three series. The C series products are expected to launch in 2025, bringing a new revolution in beauty to the market.

Currently, Xienfei (Beijing) Technology and Trade Co., Ltd. is actively engaged in the clinical trial of this project, with the product expected to launch in 2026 as the V series. The launch of the V series not only marks another major breakthrough in Xienfei's product layout in the injectable cross-linked sodium hyaluronate field but also represents a comprehensive upgrade in both depth and breadth of its product line. As various series of REJUVIEL products successively debut, consumers will have more choices and experience more personalized, efficient, and safe beauty solutions. The launch of this clinical trial demonstrates Xienfei's firm belief in continuous exploration and innovation in the medical aesthetics and medical device field, indicating that its new products will lead industry trends and open a new chapter in healthy beauty with safer and more efficient solutions.